Table 2.
Stage 2 Baseline Characteristics by treatment group
| CoQ10 2,700mg n=75 | Placebo n=75 | |
|---|---|---|
| Mean age in years (SD) | 56.5 (10.8) | 57.4 (11.0) |
| Gender, n (%) | ||
| Male | 40 (53.3%) | 46 (61.3%) |
| Female | 35 (46.7%) | 29 (38.7%) |
| Race, n (%) | ||
| White | 71 (94.7%) | 71 (94.7%) |
| Black | 3 (4.0%) | 1 (1.3%) |
| Asian | 1 (1.3%) | 1 (1.3%) |
| More than one | 0 (0.0%) | 1 (1.3%) |
| Other | 0 (0.0%) | 1 (1.3%) |
| Ethnicity, n (%) | ||
| Not Hispanic/Latino | 73 (97.3%) | 72 (96.0%) |
| Hispanic/Latino | 2 (2.7%) | 3 (4.0%) |
| Mean Symptom duration in years (SD) | 2.3 (1.1) | 2.0 (1.3) |
| Site of onset, n (%) | ||
| Lower extremity | 30 (40.0%) | 34 (45.3%) |
| Upper extremity | 34 (45.3%) | 28 (37.3%) |
| Head | 11 (14.7%) | 13 (17.3%) |
| Mean ALSFRS-R score (SD) | 35.3 (5.5) | 35.6 (5.0) |
| Mean FVC, % of predicted (SD) | 87.7 (23.6) | 89.2 (18.2) |
| Mean BMI‡ (SD) | 26.8 (7.0) | 26.2 (4.6) |
| Riluzole use, n (%) | 57 (76.0%) | 50 (66.7%) |
| Mean CoQ10 level (SD) | 1.0 (0.44) | 0.90 (0.35) |
‡
Total n=149
SD=Standard Deviation